30 results
8-K
COGT
Cogent Biosciences Inc
11 Dec 23
Other Events
8:04am
for bezuclastinib’s safety and tolerability profile to support chronic dosing for patients with NonAdvSM; plans for the Company to initiate Part 2 of SUMMIT
424B5
COGT
Cogent Biosciences Inc
15 Jun 22
Prospectus supplement for primary offering
5:16pm
on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia (CMML) transformed to acute myeloid leukemia (AML) and discontinued
424B5
COGT
Cogent Biosciences Inc
13 Jun 22
Prospectus supplement for primary offering
6:11am
, all patients remained on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia (CMML) transformed to acute myeloid leukemia (AML
8-K
EX-99.1
flslh 2ktp9uruc
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
8-K
EX-99.2
xlvlynyq 0x8c38iz
10 Jun 22
Submission of Matters to a Vote of Security Holders
7:12am
424B5
xocv5d9jws3wm8tbcqb3
2 Dec 20
Prospectus supplement for primary offering
5:06pm
424B5
tp9m9r8k
30 Nov 20
Prospectus supplement for primary offering
5:28pm
DEFM14A
64gp5owv6ei
9 Oct 20
Proxy related to merger
4:44pm
8-K
EX-99.2
061w1aim ydw3b
5 Oct 20
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
9:08am
8-K
EX-99.1
p25ux
11 Aug 20
Unum Therapeutics Reports Second Quarter 2020
5:02pm
8-K
EX-99.2
fr2vn6 vady
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am